hypophosphatemia%20-and-%20hyperphosphatemia
HYPOPHOSPHATEMIA & HYPERPHOSPHATEMIA

Hypophosphatemia is an electrolyte imbalance where there is a decrease in the serum phosphate level that is less than the normal range.

It is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.

It may be transient and reflect intracellular shift with minimal clinical consequences.

Hyperphosphatemia is an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present.

Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.

The significant level of hyperphosphatemia in adults is >6 mg/dL.

Monitoring

Monitoring of Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients
  • Monitoring of serum phosphate in CKD patients should start in patients w/ grade 3 CKD
    • Frequency of monitoring will be based on the presence & magnitude of abnormalities & the rate of progression of the disease
  • Monitoring of serum phosphate intervals may be as followed:
    • Every 6-12 months in patients w/ grade 3 CKD
    • Every 3-6 months in patients w/ grade 4 CKD
    • Every 1-3 months in patients w/ grade 5 CKD
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
23 hours ago
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

5 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.